Survodutide is a once-weekly injectable peptide developed by Boehringer Ingelheim under license from Zealand Pharma, designed to activate both the GLP-1 and glucagon receptors. It posted its first Phase 3 obesity results in April 2026, adding a third major dual- or triple-receptor candidate, alongside retatrutide and tirzepatide, to the pipeline of drugs built on more than one hormone target.
What It Is and How It Works
Survodutide is a dual glucagon/GLP-1 receptor agonist. The GLP-1 component works the same way as approved drugs like semaglutide, slowing digestion and reducing appetite. The added glucagon-receptor activity acts primarily on the liver, where it’s thought to increase fat breakdown and reduce hepatic fat content — a mechanism the companies are also studying specifically for liver disease, not obesity alone.
The SYNCHRONIZE-1 Phase 3 Results
In the SYNCHRONIZE-1 trial, participants on survodutide (weekly injections of 3.6 mg or 6.0 mg) lost an average of 16.6% of body weight over 76 weeks — up to about 39 pounds — compared with 3.2% on placebo. Just over 85% of participants on survodutide reached at least 5% weight loss, versus roughly 39% on placebo. Boehringer Ingelheim announced the topline results in April 2026 and said full data would be presented at the American Diabetes Association’s June 2026 Scientific Sessions.
Regulatory Status
Survodutide is not FDA-approved for any use. SYNCHRONIZE-1 is one of several ongoing Phase 3 trials, alongside SYNCHRONIZE-2, SYNCHRONIZE-MASLD, SYNCHRONIZE-CVOT, and the separate LIVERAGE program studying survodutide for liver disease specifically. No approval application had been announced as of this writing, and the drug remains investigational.
How It Differs From Single-Target GLP-1 Drugs
Survodutide’s glucagon-receptor activity is the main mechanistic difference from single-target drugs like semaglutide, and it distinguishes it from tirzepatide’s GLP-1/GIP combination as well. Whether the added glucagon target translates into a meaningfully different clinical profile beyond the topline weight-loss numbers is something later trial data, including the liver-focused LIVERAGE studies, will need to establish through direct comparison rather than through current single-arm topline figures alone.
Safety Signals So Far
Boehringer Ingelheim reported that gastrointestinal events were the most common side effect, with discontinuations occurring more frequently during dose escalation, and described the events as generally mild to moderate and temporary. The company said no new safety concerns emerged beyond those already expected for the broader GLP-1 drug class, though this is still trial-phase data from a defined study population, not a long-term safety record.
The Bottom Line
Survodutide’s Phase 3 results put it in the same general weight-loss range as approved GLP-1/GIP drug tirzepatide, based on cross-trial comparisons that should be read cautiously given differences in trial design and populations. It remains an investigational drug with no FDA approval, and its future availability depends on the outcome of its ongoing Phase 3 program and any eventual approval application.